$39.35
+2.42%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$38.92
From 52W high−38.50%
Volume9.09M
Market cap$175.70B
P/E (TTM)10.0x
P/S (TTM)3.6x
Div yield3.80%
Key dataOct 20, 2026
Open
$38.92
From 52W high
−38.50%
Volume
9.09M
Market cap
$175.70B
ValuationView details →
P/E (Fwd)
11.8x
EV/EBITDA
7.0x
P/E (TTM)
10.0x
RSI (14)
46.3
MomentumView details →
1D Return
+2.42%
YTD Return
−22.94%
SummaryUpdated Jun 1, 2026
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.
Similar companies
Latest newsMore news →
NOVO NORDISK A S shares rose more than 2% on Tuesday.16h agoNOVO NORDISK A S reported a new analysis showing average weight loss of 25% after 68 weeks among adult women treated with experimental CagriSema.18h agoChina’s National Medical Products Administration approved updated product information allowing NOVO NORDISK A S’s Wegovy semaglutide injection to be stored at 2°C–30°C for up to 48 hours before first opening during distribution to patients.2d ago